Display options
Cite
Ernst S, Garro OA, Winkler S, et al. Process simulation for recombinant protein production: cost estimation and sensitivity analysis for heparinase I expressed in Escherichia coli. Biotechnol Bioeng. 1997;53(6):575-82doi: 10.1002/(SICI)1097-0290(19970320)53:6<575::AID-BIT5>3.0.CO;2-J.
Ernst, S., Garro, O. A., Winkler, S., Venkataraman, G., Langer, R., Cooney, C. L., & Sasisekharan, R. (1997). Process simulation for recombinant protein production: cost estimation and sensitivity analysis for heparinase I expressed in Escherichia coli. Biotechnology and bioengineering, 53(6), 575-82. https://doi.org/10.1002/(SICI)1097-0290(19970320)53:6<575::AID-BIT5>3.0.CO;2-J
Ernst, S, et al. "Process simulation for recombinant protein production: cost estimation and sensitivity analysis for heparinase I expressed in Escherichia coli." Biotechnology and bioengineering vol. 53,6 (1997): 575-82. doi: https://doi.org/10.1002/(SICI)1097-0290(19970320)53:6<575::AID-BIT5>3.0.CO;2-J
Ernst S, Garro OA, Winkler S, Venkataraman G, Langer R, Cooney CL, Sasisekharan R. Process simulation for recombinant protein production: cost estimation and sensitivity analysis for heparinase I expressed in Escherichia coli. Biotechnol Bioeng. 1997 Mar 20;53(6):575-82. doi: 10.1002/(SICI)1097-0290(19970320)53:6<575::AID-BIT5>3.0.CO;2-J. PMID: 18634058.
Copy Download .nbib Format: NLM
Share it on

Biotechnol Bioeng. 1997 Mar 20;53(6):575-82. doi: 10.1002/(SICI)1097-0290(19970320)53:6<575::AID-BIT5>3.0.CO;2-J.

Process simulation for recombinant protein production: cost estimation and sensitivity analysis for heparinase I expressed in Escherichia coli.

Biotechnology and bioengineering

S Ernst, O A Garro, S Winkler, G Venkataraman, R Langer, C L Cooney, R Sasisekharan

Affiliations

  1. Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.

PMID: 18634058 DOI: 10.1002/(SICI)1097-0290(19970320)53:6<575::AID-BIT5>3.0.CO;2-J

Abstract

Heparinase I from flavobacterium heparinum has several potential clinical applications; the resulting high demands on protein purity and quantity can be met by recombinant expression in Escherichia coli. Based on laboratory scale experiments with insoluble heparinase I expression followed by renaturation, a process for production of 3 kg/year of heparinase I was designed. We present a comparative analysis of the production costs of soluble and insoluble heparinase I expression, as well as a generalized approach to sensitivity analysis, based on perturbation around a base case design scenario. This may assist focusing further development on process steps for which improvements both are feasible and result in significant cost saving.

Publication Types